Nasdaq:US$18.03 (+0.20) | HKEX:HK$27.90 (-0.30) | AIM:£2.85 (+0.05)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases | 29 Oct 2022

NANETS 2022:An open-label, Phase 1b/2 study of surufatinib in combination with tislelizumab in patients with advanced neuroendocrine tumors